Cartesian Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDCartesian Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 91), indicating clear outperformance against the broad market. Earnings contraction of 115% provides fundamental context to the price action. However, price is extended 26% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $9.21 | +9.11% | ABOVE |
| 50 SMA | $7.95 | +26.39% | ABOVE |
| 100 SMA | $7.40 | +35.74% | ABOVE |
| 150 SMA | $7.35 | +36.69% | ABOVE |
| 200 SMA | $7.70 | +30.44% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RNAC in an uptrend right now?
RNAC has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is RNAC overbought or oversold?
RNAC's RSI (14) is 62. The stock is in neutral territory, neither overbought nor oversold.
Is RNAC outperforming the market?
RNAC has a Relative Strength (RS) Rating of 91 out of 99. Yes, RNAC is a market leader, outperforming 91% of all stocks over the past 12 months.
Where is RNAC in its 52-week range?
RNAC is trading at $10.05, which is 65% of its 52-week high ($15.57) and 45% above its 52-week low ($5.60).
How volatile is RNAC?
RNAC has a Beta of 1.79 and 52-week volatility of 89%. It's more volatile than the S&P 500 - expect bigger swings.